Table 2.
Sample designation | Total length (nucleotides) | Number and nature of non-conserved bases | Position in sequence alignment | Sequencing platform used: on PCR1 | Sequencing platform used: on PCR2 |
---|---|---|---|---|---|
Group 1 | |||||
ME.2013.0131 | 11924 | 0 | Both1 | - | |
NB.2014.0941 | 11924 | 0 | Both1 | - | |
NY.2004.2473 | 11924 | 0 | Both1 | - | |
ON.2005.4941 | 11925 | 1, R by both reads | 6880 | Both2 | - |
VT.2006.0225 | 11923 | 1, R by Illumina, G by Sanger | 4302 | Both2 | - |
VT.2011.0122 | 11923 | 1, G by Illumina, K by Sanger | 3780 | Both1 | - |
Group 2 | |||||
ON.2003.1519 | 11925 | 0 | Illumina2 | Sanger1 | |
ON.2003.2760 | 11925 | 0 | Illumina1 | Sanger1 | |
VT.2006.0259 | 11924 | 0 | Sanger1 | Sanger4 | |
VT.2007.0522 | 11925 | 1, G (PCR1), R (PCR2) | 4308 | Illumina3 | Sanger4 |
VT.2008.0209 | 11925 | 0 | Sanger1 | Sanger4 | |
VT.2008.0237 | 11923 | 1, R (PCR1), G (PCR2) | 4894 | Sanger1 | Sanger4 |
VT.2011.0122 | 11923 | 0 | Illumina1 | Sanger4 |
amplified as three fragments A, B, C
amplified as four fragments A1, A2, B, C
amplified as four fragments A, B C1 and C2
amplified as six fragments A1, A2, B1, B2, C1, C2